يعرض 1 - 10 نتائج من 31 نتيجة بحث عن '"factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS]"', وقت الاستعلام: 1.17s تنقيح النتائج
  1. 1

    المساهمون: Institut Català de la Salut, [Isla D] Hospital Clínico Universitario Lozano Blesa, IIS Aragón, Sociedad Española de Oncología Médica (SEOM), Zaragoza, Spain. [Lozano MD] Clínica Universidad de Navarra, Sociedad Española de Citología (SEC), Sociedad Española de Anatomía Patológica (SEAP), Pamplona, Spain. [Paz-Ares L] Hospital Universitario 12 de Octubre, Sociedad Española de Oncología Médica (SEOM), Madrid, Spain. [Salas C] Hospital Universitario Puerta de Hierro, Sociedad Española de Anatomía Patológica (SEAP), Madrid, Spain. [de Castro J] Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Sociedad Española de Oncología Médica (SEOM), Madrid, Spain. [Conde E] Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital Universitario 12 de Octubre (i+12), Sociedad Española de Anatomía Patológica (SEAP), Madrid, Spain. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Sociedad Española de Oncología Médica (SEOM), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  2. 2

    المساهمون: Institut Català de la Salut, [Vera R] Navarra University Hospital, Spanish Society of Medical Oncology (SEOM), Pamplona, Spain. [Ibarrola-de-Andrés C, Rodríguez-Gil Y] 12 de Octubre University Hospital, Spanish Society of Pathology (SEAP), Madrid, Spain. [Adeva J] 12 de Octubre University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. [Pérez-Rojas J] La Fe University and Polytechnic Hospital, Spanish Society of Pathology (SEAP), Valencia, Spain. [García-Alfonso P] Gregorio Marañón University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Society of Medical Oncology (SEOM), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: CLINICAL & TRANSLATIONAL ONCOLOGY
    r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
    instname
    Scientia

    وصف الملف: application/pdf

  3. 3

    المساهمون: Institut Català de la Salut, [Lombaers MS] Department of Obstetrics and Gynaecology, Radboud University Medical Center, GA Nijmegen, The Netherlands. Radboud Institute of Health Sciences, GA Nijmegen, The Netherlands. [Cornel KMC] Department of Obstetrics and Gynaecology, Radboud University Medical Center, GA Nijmegen, The Netherlands. Department of Obstetrics and Gynecology, Division Gynecologic Oncology, University of Toronto, Toronto, Canada. [Visser NCM] Department of Pathology, Eurofins PAMM, Eindhoven, The Netherlands. [Bulten J] Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands. [Küsters-Vandevelde HVN] Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands. [Amant F] Department of Oncology, KU Leuven, Leuven, Belgium. Center for Gynecologic Oncology Amsterdam, Netherlands Cancer Institute and Amsterdam University Medical Center, Amsterdam, The Netherlands. [Colas E] Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red Cáncer, Barcelona, Spain. [Gil-Moreno A] Grup de Recerca Biomèdica en Ginecologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red Cáncer, Barcelona, Spain. Servei de Ginecologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red Cáncer, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  4. 4
  5. 5

    المساهمون: Institut Català de la Salut, [Pestana RC] Hospital Israelita Albert Einstein, São Paulo, Brazil. [Serrano C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Sarcoma Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  6. 6

    المساهمون: Institut Català de la Salut, [Garassino MC] Section of Hematology/Oncology, Thoracic Oncology program, University of Chicago, Chicago, Illinois, and IRCCS Istituto Nazionale dei Tumori, Milano. [Gadgeel S] Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System, Detroit, Michigan. [Novello S] Department of Oncology, University of Turin, Orbassano, Italy. [Halmos B] Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York. [Felip E] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Speranza G] Centre integré de cancérologie de la Montérégie, Université de Sherbrooke, Greenfield Park, Quebec, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  7. 7

    المساهمون: Institut Català de la Salut, [Strand SH] Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. [Rivero-Gutiérrez B, Risom T] Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. [Houlahan KE] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. [Seoane JA] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [King LM] Department of Surgery, Duke University School of Medicine, Durham, NC 27708, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia
    Strand, S H, Rivero-Gutiérrez, B, Houlahan, K E, Seoane, J A, King, L M, Risom, T, Simpson, L A, Vennam, S, Khan, A, Cisneros, L, Hardman, T, Harmon, B, Couch, F, Gallagher, K, Kilgore, M, Wei, S, DeMichele, A, King, T, McAuliffe, P F, Nangia, J, Lee, J, Tseng, J, Storniolo, A M, Thompson, A M, Gupta, G P, Burns, R, Veis, D J, DeSchryver, K, Zhu, C, Matusiak, M, Wang, J, Zhu, S X, Tappenden, J, Ding, D Y, Zhang, D, Luo, J, Jiang, S, Varma, S, Anderson, L, Straub, C, Srivastava, S, Curtis, C, Tibshirani, R, Angelo, R M, Hall, A, Owzar, K, Polyak, K, Maley, C, Marks, J R, Colditz, G A, Hwang, E S & West, R B 2022, ' Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ : Analysis of TBCRC 038 and RAHBT cohorts ', Cancer Cell, vol. 40, no. 12, pp. 1521-1536.e7 . https://doi.org/10.1016/j.ccell.2022.10.021Test

    وصف الملف: application/pdf

  8. 8

    المساهمون: Institut Català de la Salut, [Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Díaz-Gómez J, Grases D, Pasamar H, Gros A] Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  9. 9

    المساهمون: Institut Català de la Salut, [Saura C, Oliveira M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Innovative Breast Cancer Research, Barcelona, Spain. [Matito J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Wildiers H] University Hospitals Leuven, Leuven, Belgium. [Brufksy AM] Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania. [Waters SH] Velindre Cancer Centre, Cardiff, Wales, United Kingdom. [Vivancos A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. SOLTI Innovative Breast Cancer Research, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES], Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Breast Neoplasms, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Lapatinib, Quimioteràpia combinada, Capecitabine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, In patient, Neoplasm Metastasis, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], Correlation of Data, skin and connective tissue diseases, neoplasms, neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES], business.industry, Proportional hazards model, Marcadors tumorals, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.disease, Metastatic breast cancer, Confidence interval, Retreatment, Mama - Càncer - Tractament, Neratinib, Quinolines, Immunohistochemistry, Female, business, medicine.drug

    وصف الملف: application/pdf; Print-Electronic

  10. 10

    المساهمون: Institut Català de la Salut, [Peters S] Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland. [Dziadziuszko R] Medical University of Gdańsk, Gdańsk, Poland. [Morabito A] Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Naples, Italy. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gadgeel SM] Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA. [Cheema P] William Osler Health System, University of Toronto, Brampton, Ontario, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Lung Neoplasms, phase 3 trial, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Marcadors tumorals, terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], blood-based tumor, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Atezolizumab versus chemotherapy, NSCLC, blood-based tumor, mutational burden, phase 3 trial, General Medicine, Pulmons - Càncer - Immunoteràpia, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], NSCLC, Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/drug therapy [Other subheadings], General Biochemistry, Genetics and Molecular Biology, Atezolizumab versus chemotherapy, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Immunotherapy, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], mutational burden

    وصف الملف: application/pdf